Gilead Sciences, Inc. Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment of Chronic Lymphocytic Leukemia

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-11…
Read the full story: BioSpace.com Featured News